Literature DB >> 18058366

Radiation-induced EGFR-signaling and control of DNA-damage repair.

H Peter Rodemann1, Klaus Dittmann, Mahmoud Toulany.   

Abstract

PURPOSE: Over the last decade evidence has accumulated indicating that cell membrane-bound growth factor receptor of the erbB family and especially the epidermal growth factor receptor EGFR (erbB1) mediates resistance of tumor cells to both chemo- and radiotherapy when mutated or overexpressed. More recently a novel link between EGFR signaling pathways and DNA repair mechanisms, especially non-homologous end joining (NHEJ) repair could be demonstrated. The following review summarizes the current knowledge on the role of EGFR and its downstream signaling pathways in the regulation of cellular radiation response and DNA repair.
CONCLUSION: The novel findings on radiation-induced EGFR-signaling and its involvement in regulating DNA-double strand break repair need further investigations of the detailed mechanisms involved. The results to be obtained may not only improve our knowledge on basic mechanisms of radiation sensitivity/resistance but also will promote translational approaches to test new strategies for clinically applicable molecular targeting.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18058366     DOI: 10.1080/09553000701769970

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  75 in total

1.  Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.

Authors:  Chunrong Li; Toni M Brand; Mari Iida; Shyhmin Huang; Eric A Armstrong; Albert van der Kogel; Deric L Wheeler
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

2.  Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.

Authors:  M Saki; M Toulany; W Sihver; M Zenker; J-M Heldt; B Mosch; H-J Pietzsch; M Baumann; J Steinbach; H P Rodemann
Journal:  Strahlenther Onkol       Date:  2012-08-10       Impact factor: 3.621

3.  EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.

Authors:  Gianmaria Liccardi; John A Hartley; Daniel Hochhauser
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

4.  Demonstration of Tightly Radiation-Controlled Molecular Switch Based on CArG Repeats by In Vivo Molecular Imaging.

Authors:  Ya-Ju Hsieh; Luen Hwu; Chien-Chih Ke; Ai-Lin Huang; Fu-Du Chen; Shyh-Jong Wu; Sharon Chia-Ju Chen; Yong-Hua Zhao; Ren-Shyan Liu
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

Review 5.  DNA double-strand break - induced pro-survival signaling.

Authors:  Amy J Hawkins; Sarah E Golding; Ashraf Khalil; Kristoffer Valerie
Journal:  Radiother Oncol       Date:  2011-07-02       Impact factor: 6.280

Review 6.  [Molecular signaling pathways. Mechanisms and clinical use].

Authors:  N Cordes; F Rödel; H-P Rodemann
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

Review 7.  Effects of irradiation on tumor cell survival, invasion and angiogenesis.

Authors:  Odysseas Kargiotis; Aliki Geka; Jasti S Rao; Athanasios P Kyritsis
Journal:  J Neurooncol       Date:  2010-05-07       Impact factor: 4.130

8.  Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.

Authors:  Lei Duan; Ricardo E Perez; Michael Hansen; Steven Gitelis; Carl G Maki
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

9.  Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models.

Authors:  Hanneke Stegeman; Johannes H Kaanders; Albert J van der Kogel; Mari Iida; Deric L Wheeler; Paul N Span; Johan Bussink
Journal:  Radiother Oncol       Date:  2013-02-28       Impact factor: 6.280

Review 10.  Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function.

Authors:  Klaus Dittmann; Claus Mayer; H Peter Rodemann
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.